Soleno Therapeutics Submits NDA To The U.S. FDA For DCCR (Diazoxide Choline) Extended-Release Tablets For The Treatment Of Prader-Willi Syndrome
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics has submitted a New Drug Application to the FDA for DCCR extended-release tablets aimed at treating Prader-Willi syndrome in individuals aged four and older with hyperphagia.
June 28, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Soleno Therapeutics has submitted an NDA to the FDA for DCCR tablets to treat Prader-Willi syndrome, a significant step in the regulatory process that could lead to market approval and commercialization.
The submission of an NDA is a critical milestone for any biopharmaceutical company. If approved, it could lead to the commercialization of DCCR tablets, potentially driving revenue growth and increasing the stock price. The high relevance and importance scores reflect the direct impact on Soleno's business prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100